Evolus Inc. Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements
Reuters
Sep 16
Evolus Inc. Unveils Scientific Investor Presentation Highlighting Innovative Aesthetic Technologies and Clinical Advancements
Evolus Inc. has presented a scientific investor presentation highlighting its advancements in aesthetics and medical biomaterials. The presentation showcases Evolysse, an innovative technology that complements the Jeuveau® brand. Evolysse demonstrates non-inferiority and statistical superiority at six months compared to Restylane-L in a pivotal trial, with significance maintained through 12 months. The company emphasizes its unique HI-PURE manufacturing process and Cold-X technology, which preserve the natural structure of the HA molecule. Symatese, the company behind this innovation, has over 25 years of experience in R&D and launched its first two products, Hemotese® and Collapat®II. The presentation also notes a strengthened R&D partnership with L'Oréal on biomaterials. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief on September 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.